Phase 01 Clinical Trials

LMP和DCTD之间的合作负责开发几种新的药效学分析，包括肿瘤组织活检中伽马H2AX （DNA双链断裂检测器）的超灵敏免疫荧光分析，以及拓扑异构酶I和聚adp核糖聚合酶（PARP）的elisa。这些检测对于PARP抑制剂联合拓扑异构酶I抑制剂以及NIH临床中心激活的新型非喜树碱拓扑异构酶I抑制剂的首次人体临床试验至关重要。此外，与肿瘤医学处的合作促进了新型DNA甲基转移酶抑制剂氟脱氧胞苷与四氢吡啶联合使用的开发，这些药物已由DCTD生产，供CCR研究。围绕我们在系统药理学中使用NCI 60，已经开展了更多的合作。

The collaboration between the LMP and DCTD has been responsible for the development of several new pharmacodynamic assays, including an ultrasensitive immunofluorescence assay for gamma H2AX (DNA double strand break detector) in tumor tissue biopsies, and ELISAs for topoisomerase I and poly ADP-ribose polymerase (PARP). These assays have been essential for first in human clinical trials of PARP inhibitors in combination with topoisomerase I inhibitors as well as of novel, non-camptothecin topoismerase I inhibitors that have been activated in the NIH Clinical Center. In addition, collaborations with the Medical Oncology Branch have facilitated the development of the new DNA methyltransferase inhibitor fluorodeoxycytidine used in combination with tetrahydrouridine, drugs that have been produced by DCTD for study by the CCR. Additional collaborations have developed around our use of the NCI 60 for systems pharmacology.